Hypothesis

We propose that aging induces a compensatory increase in occludin expression, particularly in the descending colon, that alters the ZO‑1:occludin stoichiometry and creates selective paracellular channels permissive to low‑molecular‑weight bacterial products (e.g., LPS) while restricting larger macromolecules. This selective leak fuels systemic inflammaging without causing gross barrier breakdown.

Mechanistic Basis

• Human biopsy data show stable ZO‑1, claudin‑2, JAM‑A and elevated occludin in the descending colon with age 1.
• Aging‑related CB1 downregulation raises miR‑191‑5p and NF‑κB p65 activity, which suppresses ZO‑1 but can simultaneously drive occludin transcription as a NF‑κB‑dependent feedback loop 2.
• Impaired Rab prenylation and HSF‑1 loss disrupt apical trafficking, leading to mislocalized occludin that accumulates at the lateral membrane rather than the tight junction strand 3.
• The resulting ZO‑1 deficiency weakens scaffold anchoring, while excess occludin forms aberrant oligomers that widen pore size or alter charge selectivity, permitting LPS (~10 kDa) to pass but excluding larger dextran tracers (>70 kDa).

Testable Predictions

1. The ZO‑1:occludin protein ratio in descending colon biopsies will inversely correlate with serum LPS‑binding protein (LBP) and IL‑6 levels across the adult lifespan.
2. Selective permeability assays using fluorescein‑isothiocyanate (FITC)‑labeled 4 kDa dextran versus 70 kDa dextran will show increased flux of the small tracer but not the large one in aged intestinal epithelia.
3. Exogenous occludin overexpression in intestinal organoids derived from aged donors will recapitulate the selective LPS permeability phenotype, whereas ZO‑1 knockdown alone will produce non‑selective leak.
4. Pharmacological CB1 activation in aged mice will normalize the ZO‑1:occludin ratio, reduce LPS translocation, and lower circulating TNF‑α and IL‑6.

Experimental Approach

• Obtain paired colonic biopsies (descending colon) from young (20‑35 y) and older (>65 y) donors; quantify ZO‑1 and occludin by Western blot and immunofluorescence, calculate ratio, and measure serum LBP, IL‑6, TNF‑α.
• Use Ussing chambers with mounted colonic mucosa to assess FITC‑dextran flux of 4 kDa and 70 kDa; correlate with biomarker levels.
• Generate colonic organoids from biopsies; manipulate occludin or ZO‑1 via CRISPRi or lentiviral overexpression; assess LPS translocation using ELISA‑based LPS detection in basal media.
• Treat aged rats with CB1 agonist (e.g., ACEA) for 2 weeks; repeat biopsy and permeability assays.

Potential Implications

If validated, this hypothesis reframes the "leaky gut" concept: barrier dysfunction in aging may be a qualitative shift in pore selectivity rather than a quantitative loss of seal. It offers a mechanistic link between cannabinoid signaling, tight junction stoichiometry, and systemic inflammaging, suggesting that normalizing ZO‑1:occludin balance—rather than globally tightening junctions—could mitigate age‑related inflammation.